Primary-source investigative reporting on FDA votes, regulatory filings, clinical trials, and laboratory purity testing.
Aizen Therapeutics, a San Diego-based AI biotech spun out of Caltech, has entered a multi-program collaboration with an undisclosed public partner. The deal includes upfront funding and up to $100 million in milestone payments per target.
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23 to recommend placing BPC-157, TB-500, and other peptides on the agency's bulks list, a shift that follows years of promotion by Joe Rogan, RFK Jr., and wellness clinic.
The drugmaker is suing four online peptide sellers, a California med spa, and a compounding pharmacy for marketing an unapproved triple-receptor agonist to consumers under a 'research use' label.
Eli Lilly filed six federal lawsuits against compounding pharmacies, med spas, and online sellers marketing unapproved retatrutide as 'research-use only,' challenging a labeling convention the drugmaker says conceals illegal human.
An FDA advisory panel narrowly recommended reclassifying four unapproved peptides from a prohibited-compounding category to one that permits licensed pharmacies to prepare them. The vote does not constitute drug approval, and formal.
FDA staff scientists recommended against every peptide under review. The advisory panel voted six through anyway, citing grey-market harm. Formal rulemaking now determines whether compounding pharmacies gain legal access.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding six peptides to the 503A compounding list, directly contradicting the agency's own scientific staff. The vote is.
A narrowly composed FDA advisory panel recommended placing six unproven peptides into a category that permits pharmacy compounding, over the objections of career scientists. The vote follows HHS Secretary RFK Jr.'s personal advocacy and.
Mike McKnight told Cam Hanes' podcast audience that BPC-157 healed his herniated disc and let him cancel surgery. USADA prohibits the peptide at all times. The FDA just voted to let compounding pharmacies make it.
The USC gerontologist who identified MOTS-c is sounding the alarm on a thriving online trade that sells the mouse-exercise peptide to consumers without purity or sterility guarantees.
The Mequon, Wis., contract lab announced an expanded quality analytical testing platform for peptides, with Vector Science & Therapeutics as its first named client under a LyoGenesis Holdings agreement.